News

Deal Announcements

Acylin Therapeutics Lands $2 Million Series A

Tuesday, June 5, 2012 5:32:00 AM PDT | VentureDeal
Seattle, Washington  --  Biotechnology company Acylin Therapeutics has received $2 million in new venture capital investment, according to an SEC regulatory filing.

Acylin is developing inhibitors of cellular acylation, which is an enzymatic mechanism fundamental to the molecular pathology of cancer and other diseases.

Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1